LIVZON PHARMA (01513) intends to acquire approximately 0.13% of the shares in Xinbeijiang Pharmaceutical held by Zhonghuiyuan.

LIVZON PHARMA (01513) announces that on November 11, 2026, the Company entered into a Xinbeijiang Pharmaceutical share transfer agreement with Zhonghuiyuan, pursuant to which the Company agreed to acquire approximately 0.13% of the shares in Xinbeijiang Pharmaceutical held by Zhonghuiyuan for a cash consideration of approximately RMB3.8525 million (corresponding to approximately RMB303,600 of the registered capital of Xinbeijiang Pharmaceutical). Upon completion of the Xinbeijiang Pharmaceutical share acquisition, the Company's direct interest in Xinbeijiang Pharmaceutical will increase from approximately 90.64% to approximately 90.77%. Zhonghuiyuan, as the employee shareholding platform of Xinbeijiang Pharmaceutical, in order to further optimize the equity structure of Xinbeijiang Pharmaceutical, strengthen the Company's control over its core active pharmaceutical ingredient subsidiary, and improve operational decision-making efficiency, the Company intends to acquire part of the shares in Xinbeijiang Pharmaceutical held by Zhonghuiyuan. This transaction is a normal operating arrangement for the Company to optimize subsidiary governance and deepen its industrial layout, is in line with the Company's overall development strategic plan, and is in line with the Company's long-term development interests and the overall interests of all shareholders. This transaction will not cause any material change to the Company's financial position and operating results for the current period and in the future, and will not have any adverse impact on the Company's daily operations.